Aviragen Therapeutics Inc (AVIR)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Aviragen Therapeutics Inc (AVIR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012254
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aviragen Therapeutics Inc (Aviragen) is a pharmaceutical company that carries out anti-infective drug discovery, development and its commercialization to treat respiratory diseases. It has four product candidates in clinical development which address viral infections, namely, vapendavir, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus; BTA074, a Phase 2 topical antiviral treatment for genital warts; BTA585, an oral fusion protein inhibitor that Aviragen is developing for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a long-acting neuraminidase inhibitor for influenza A and B infections. The Company also has a preclinical RSV non-fusion inhibitor program for its F-protein inhibitor BTA585. Aviragen is headquartered in Alpharetta, Georgia, the US.

Aviragen Therapeutics Inc (AVIR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Aviragen Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 11
Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
AMRI Enters Into Co-Development Agreement With Biota Holdings For CS8958 13
Merger 14
Aviragen Therapeutics to Merge with Vaxart 14
Nabi Biopharma Completes Merger With Biota 15
Licensing Agreements 17
Aviragen Therapeutics Enters into Licensing Agreement with Georgia State University Research Foundation 17
Equity Offering 18
Biota Pharma Plans to Raise USD25 Million in Public offering of Shares 18
Biota Pharma Completes Public Offering Of shares For US$29 Million 19
Asset Transactions 21
Spero Therapeutics Acquires Antibiotic Assets from Biota Pharma (Aviragen Therapeutics) 21
Acquisition 22
Biota Pharma Acquires Anaconda Pharma for up to USD38 Million 22
Aviragen Therapeutics Inc – Key Competitors 23
Aviragen Therapeutics Inc – Key Employees 24
Aviragen Therapeutics Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Nov 02, 2017: Aviragen Therapeutics Reports First Quarter of Fiscal Year 2018 Financial Results 26
Aug 31, 2017: Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results 28
May 04, 2017: Aviragen Therapeutics Reports Third Quarter Fiscal Year 2017 Financial Results 29
Feb 02, 2017: Aviragen Therapeutics Reports Second Quarter Fiscal Year 2017 Financial Results 30
Nov 03, 2016: Aviragen Therapeutics Reports First Quarter Fiscal Year 2017 Financial Results 32
Sep 14, 2016: Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2016 Financial Results 34
May 05, 2016: Aviragen Therapeutics Reports Third Quarter Fiscal Year 2016 Financial Results 36
Feb 05, 2016: Biota Pharmaceuticals Reports Second Quarter Fiscal Year 2016 Financial Results 38
Clinical Trials 40
Feb 01, 2017: Aviragen Therapeutics Announces Top-Line Results from Phase 2a RSV Challenge Study of BTA585 40
Jul 12, 2016: Aviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial 41
Jul 12, 2016: Aviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial 42
May 26, 2016: Aviragen Therapeutics Provides Update on Phase 2a Trial of BTA585 for the Treatment of RSV Infections 43
Apr 11, 2016: Biota Initiates Phase 2a Efficacy Study of BTA585 for the Treatment of RSV Infections 44
Feb 26, 2016: Biota Announces Positive Results From Phase I Program for Direct Acting RSV Antiviral BTA585 45
Feb 08, 2016: Biota Commences Dosing in Phase 2 Trial of Antiviral Therapy BTA074 for Topical Treatment of Condyloma 46
Other Significant Developments 47
Apr 04, 2017: Aviragen Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update 47
Apr 12, 2016: Biota Pharmaceuticals Announces Name Change to Aviragen Therapeutics 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aviragen Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Aviragen Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 11
Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
AMRI Enters Into Co-Development Agreement With Biota Holdings For CS8958 13
Aviragen Therapeutics to Merge with Vaxart 14
Nabi Biopharma Completes Merger With Biota 15
Aviragen Therapeutics Enters into Licensing Agreement with Georgia State University Research Foundation 17
Biota Pharma Plans to Raise USD25 Million in Public offering of Shares 18
Biota Pharma Completes Public Offering Of shares For US$29 Million 19
Spero Therapeutics Acquires Antibiotic Assets from Biota Pharma (Aviragen Therapeutics) 21
Biota Pharma Acquires Anaconda Pharma for up to USD38 Million 22
Aviragen Therapeutics Inc, Key Competitors 23
Aviragen Therapeutics Inc, Key Employees 24
Aviragen Therapeutics Inc, Other Locations 25
Aviragen Therapeutics Inc, Subsidiaries 25

★海外企業調査レポート[Aviragen Therapeutics Inc (AVIR)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Showa Sangyo Co., Ltd.:企業の戦略・SWOT・財務情報
    Showa Sangyo Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Showa Sangyo Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Akashi Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Akashi Therapeutics Inc (Akashi Therapeutics), formerly DART Therapeutics Inc is a clinical stage biopharmaceutical company develops treatment for duchenne muscular dystrophy (DMD) and other rare pediatric diseases. The company provides pipeline portfolio such as HT-100, a small molecule dru …
  • iCAD Inc (ICAD):医療機器:M&Aディール及び事業提携情報
    Summary iCAD Inc (iCAD) develops and markets computer aided detection (CAD) solutions and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). iCAD products find application in detectio …
  • Biotronik SE & Co KG:企業の戦略的SWOT分析
    Biotronik SE & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Tata Chemicals Ltd (TATACHEM):企業の財務・戦略的SWOT分析
    Summary Tata Chemicals Ltd (TCL) is a chemical company engaged in offering industry, living, and farm essential chemicals. The company's products include dals, consumer salt, water purifier, soda ash, spices, sodium bicarbonate, allied chemicals, industrial salt, customized fertilizers, cement, fert …
  • Hutchison 3G UK Limited:企業の戦略・SWOT・財務分析
    Hutchison 3G UK Limited - Strategy, SWOT and Corporate Finance Report Summary Hutchison 3G UK Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Snap-on Inc (SNA):企業の財務・戦略的SWOT分析
    Snap-on Inc (SNA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Virginia Electric and Power Company:電力:M&Aディール及び事業提携情報
    Summary Virginia Electric and Power Company (Virginia Power), formerly Virginia Public Service Corporation, is a regulated energy utility that generates, transmits, and distributes electricity. It generates electricity from gas, nuclear, oil, coal, renewable, and biomass sources. The company also pr …
  • SAS Institute Inc.:企業の戦略・SWOT・財務分析
    SAS Institute Inc. - Strategy, SWOT and Corporate Finance Report Summary SAS Institute Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • InTouch Technologies Inc-医療機器分野:企業M&A・提携分析
    Summary InTouch Technologies Inc (InTouch Health) is a healthcare technology company that provides Telehealth Network, comprised of telehealth systems, clinical workflow solutions, software and managed services to healthcare systems and hospitals for the delivery of clinical care. The company’s tele …
  • Tox Free Solutions Ltd (TOX):企業の財務・戦略的SWOT分析
    Tox Free Solutions Ltd (TOX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Dr. August Oetker Kg:企業の戦略・SWOT・財務分析
    Dr. August Oetker Kg - Strategy, SWOT and Corporate Finance Report Summary Dr. August Oetker Kg - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Delta Apparel, Inc. (DLA):企業の財務・戦略的SWOT分析
    Delta Apparel, Inc. (DLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Carso Infraestructura y Construccion SA De CV:企業の戦略・SWOT・財務情報
    Carso Infraestructura y Construccion SA De CV - Strategy, SWOT and Corporate Finance Report Summary Carso Infraestructura y Construccion SA De CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, opera …
  • Metropolitan Bank and Trust Company:企業の戦略・SWOT・財務分析
    Metropolitan Bank and Trust Company - Strategy, SWOT and Corporate Finance Report Summary Metropolitan Bank and Trust Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Electromagnetic Geoservices ASA (EMGS):石油・ガス:M&Aディール及び事業提携情報
    Summary Electromagnetic Geoservices ASA (EMGS) is an oil and gas service provider that explores workflow working with seismic, petrophysical and geologic data. The company gathers controlled source electromagnetic data and conduct modeling, integration, interpretation. Its technology finds applicati …
  • Vascular Flow Technologies Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Vascular Flow Technologies Ltd (Vascular Flow) is a medical device company that develops and commercializes vascular technologies for cardiovascular devices. The company’s products include spiral flow peripheral vascular graft and spiral flow access graft. It develops vascular grafts and dru …
  • Airports of Thailand Plc (AOT):企業の財務・戦略的SWOT分析
    Airports of Thailand Plc (AOT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • China Shenhua Energy Co Ltd:企業のM&A・事業提携・投資動向
    China Shenhua Energy Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Shenhua Energy Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • AstraZeneca KK:製薬・医療:M&Aディール及び事業提携情報
    Summary AstraZeneca KK (AstraZeneca) a subsidiary of AstraZeneca Plc is a drug company that provides prescription medicines. The company offers products such as akoreto, arimidex, iressa, inderal, casodex, crestor, and other tablets. It offers products for oncology, cardiovascular and metabolic dise …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆